Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Liu, Ge ^a   Tarbet, Bart ^b   Song, Langzhou ^a   Reiserova, Lucia ^a   Weaver, Bruce ^a   Chen, Yan ^a   Li, Hong ^a   Hou, Fu ^a   Liu, Xiangyu ^a   Parent, Jason ^a   Umlauf, Scott ^a   Shaw, Alan ^a   Tussey, Lynda ^a  

^a VaxInnate Corporation   (United States)

^b UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAGELLIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; HYBRID PROTEIN; VIRUS VACCINE;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOGENICITY; MOUSE; NONHUMAN; SALMONELLA TYPHIMURIUM; ANIMAL; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; FEMALE; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; ORTHOMYXOVIRUS INFECTION; PANDEMIC; PATHOGENICITY; PROTEIN TERTIARY STRUCTURE;

MUS; SALMONELLA TYPHIMURIUM;

ANIMALS; FEMALE; FLAGELLIN; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; VIRAL VACCINES;

EID: 79958104636     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020928     Document Type: Article

References (25)

1. Langley J, Frenette L, Ferguson L, Riff D, Sheldon E, et al. (2010) Safety and Cross-reactive immunogenicity of candidate AS03-Adjuvanted prepandemic H5N1 influenza vaccines: A randomized controlled phase 1/2 trial in adults. The Journal of Infectious Diseases 201: 1644-53.
2. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, et al. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197: 667-75.
3. Lambert LC, Fauci AS, (2010) Influenza vaccines for the future. N Engl J Med 363: 2036-44.
4. Cox N, (2010) History of Influenza pandemics: lessions for the future. Options for the Control of Influenza VII: Hong Kong, 3-7 September.
5. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, et al. (2007) Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297: 1577-82.
6. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, et al. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3: e1501.
7. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, et al. (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26: 5393-9.
8. Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, et al. (2010) A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is Highly Immunogenic and Protects Mice in Active and Passive Immunizations. PLoS ONE 5: e12217.
9. Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, et al. (2009) Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 27: 5875-84.
10. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, et al. (2010) Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 5: e11548.
11. Steel J, Lowen AC, Wang T, Yondola M, Gao Q, et al. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1 (1): e00018-10.
12. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, et al. (2008) Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197: 1643-52.
13. Smith KD, ndersen-Nissen E, Hayashi F, Strobe K, Bergman MA, et al. (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4: 1247-53.
14. Song L, Nakaar V, Kavita U, Price A, Huleatt J, et al. (2008) Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 3: e2257.
15. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, et al. (2010) Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28: 8268-74.
16. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, et al. (2007) A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 195: 1607-17.
17. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-14.
18. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, et al. (2008) Influence of Prior Influenza Vaccination on Antibody and B-Cell Responses. PLoS ONE 3: e2975.
19. Hocart MJ, Mackenzie JS, Stewart GA, (1989) The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol 70 (Pt 9): 2439-48.
20. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW, (2001) Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166: 7381-8.
21. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, et al. (2006) Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza. Clin Diagn Lab Immunol 13: 981-90.
22. Tamura S, Kurata T, (2004) Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57: 236-47.
23. Ilyushina NA, Khalenkov AM, Seiler JP, Forrest HL, Bovin NV, et al. (2010) Adaptation of Pandemic H1N1 Influenza Viruses in Mice. J Virol 84: 8607-16.
24. Sidwell RW, Smee DF, Huffman JH, Barnard DL, Bailey KW, et al. (2001) In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 45: 749-57.
25. Reed LJ, Muchen H, (1938) A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 27: 493-7.